Aspiriant LLC Acquires Shares of 1,088 Cencora, Inc. (NYSE:COR)

Aspiriant LLC acquired a new stake in shares of Cencora, Inc. (NYSE:COR) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,088 shares of the company’s stock, valued at approximately $264,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Rise Advisors LLC acquired a new stake in Cencora during the first quarter valued at approximately $25,000. CVA Family Office LLC bought a new position in shares of Cencora during the first quarter valued at approximately $34,000. Bruce G. Allen Investments LLC bought a new position in shares of Cencora during the first quarter valued at approximately $43,000. Sunbelt Securities Inc. bought a new position in shares of Cencora during the first quarter valued at approximately $67,000. Finally, Trust Co. of Vermont bought a new position in shares of Cencora during the fourth quarter valued at approximately $62,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Transactions at Cencora

In related news, COO Robert P. Mauch sold 57,564 shares of the stock in a transaction on Monday, April 15th. The stock was sold at an average price of $235.09, for a total transaction of $13,532,720.76. Following the completion of the sale, the chief operating officer now directly owns 24,412 shares in the company, valued at $5,739,017.08. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, CEO Steven H. Collis sold 10,754 shares of Cencora stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $237.48, for a total value of $2,553,859.92. Following the transaction, the chief executive officer now directly owns 285,088 shares in the company, valued at $67,702,698.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Robert P. Mauch sold 57,564 shares of Cencora stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $235.09, for a total value of $13,532,720.76. Following the completion of the transaction, the chief operating officer now owns 24,412 shares in the company, valued at $5,739,017.08. The disclosure for this sale can be found here. Insiders sold a total of 1,956,675 shares of company stock valued at $422,352,056 over the last quarter. Company insiders own 15.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on COR. Robert W. Baird upped their target price on Cencora from $275.00 to $277.00 and gave the company an “outperform” rating in a report on Thursday, May 2nd. Citigroup increased their price objective on Cencora from $265.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, April 30th. Finally, StockNews.com lowered Cencora from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 2nd. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $233.90.

Cencora Price Performance

Shares of NYSE:COR opened at $237.36 on Thursday. Cencora, Inc. has a one year low of $171.65 and a one year high of $246.75. The stock has a fifty day moving average of $229.58 and a 200-day moving average of $227.67. The company has a market capitalization of $47.34 billion, a PE ratio of 25.97, a price-to-earnings-growth ratio of 1.66 and a beta of 0.48. The company has a debt-to-equity ratio of 3.41, a quick ratio of 0.53 and a current ratio of 0.89.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, May 1st. The company reported $3.80 EPS for the quarter, beating analysts’ consensus estimates of $3.65 by $0.15. Cencora had a return on equity of 268.67% and a net margin of 0.67%. The company had revenue of $68.41 billion during the quarter, compared to the consensus estimate of $70.60 billion. During the same quarter in the prior year, the firm earned $3.50 EPS. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. As a group, equities analysts anticipate that Cencora, Inc. will post 13.44 EPS for the current fiscal year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, May 24th. Stockholders of record on Friday, May 10th were given a $0.51 dividend. The ex-dividend date was Thursday, May 9th. This represents a $2.04 annualized dividend and a dividend yield of 0.86%. Cencora’s dividend payout ratio (DPR) is presently 22.32%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.